Differential host utilisation by different life history stages of the fish ectoparasite Argulus foliaceus (Crustacea: Branchiura)

Contains fulltext : 72168.pdf (publisher's version ) (Open Access

The future of religious education in Europe

This E-book is the result of a workshop on “The future of religious education in Europe”, hosted by the Robert Schuman Centre for Advanced Studies at the European University Institute in Florence on 28 October 2014.This small volume covers the entire conceptual range of approaches to religious education in public schools. The papers gathered in this publication cover the conceptual debate on the subject, ranging from a confessional approach to a sociological approach with an inclusive model as the middle-position. The different models diverge on how they define, in the context of public schooling for children aged 6 to 14 years, what religious education is aimed at: is that what should be conveyed knowledge about religion or instead religious knowledge? Should pupils become cognitively equipped to recognize and discuss religious diversity, or should they first become literate in one, presumably “their own” religious tradition?-- I Kristina Stoeckl – Knowledge about religion and religious knowledge in secular societies: introductory remarks to The future of religious education in Europe -- II Robert Jackson – Inclusive Study of Religions and other Worldviews in Publicly-funded Schools in Democratic Societies -- III Valeria Fabretti – Rethinking Religious Education sociologically: A contribution to the European debate and comparison -- IV Joachim Willems – Religious Education and the Student’s Fundamental Right to Freedom of Religion – Some Lessons and Questions from Germany -- V Matthias Scharer, Innsbruck – “Learning Religion” in the Presence of the Other: Provocation and Gift in Public Educatio

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine have been shown to be effective, but both have potentially serious adverse effects. Clopidogrel, a new thienopyridine derivative similar to ticlopidine, is an inhibitor of platelet aggregation induced by adenosine diphosphate. METHODS: CAPRIE was a randomised, blinded, international trial designed to assess the relative efficacy of clopidogrel (75 mg once daily) and aspirin (325 mg once daily) in reducing the risk of a composite outcome cluster of ischaemic stroke, myocardial infarction, or vascular death; their relative safety was also assessed. The population studied comprised subgroups of patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease. Patients were followed for 1 to 3 years. FINDINGS: 19,185 patients, with more than 6300 in each of the clinical subgroups, were recruited over 3 years, with a mean follow-up of 1.91 years. There were 1960 first events included in the outcome cluster on which an intention-to-treat analysis showed that patients treated with clopidogrel had an annual 5.32% risk of ischaemic stroke, myocardial infarction, or vascular death compared with 5.83% with aspirin. These rates reflect a statistically significant (p = 0.043) relative-risk reduction of 8.7% in favour of clopidogrel (95% Cl 0.3-16.5). Corresponding on-treatment analysis yielded a relative-risk reduction of 9.4%. There were no major differences in terms of safety. Reported adverse experiences in the clopidogrel and aspirin groups judged to be severe included rash (0.26% vs 0.10%), diarrhoea (0.23% vs 0.11%), upper gastrointestinal discomfort (0.97% vs 1.22%), intracranial haemorrhage (0.33% vs 0.47%), and gastrointestinal haemorrhage (0.52% vs 0.72%), respectively. There were ten (0.10%) patients in the clopidogrel group with significant reductions in neutrophils (< 1.2 x 10(9)/L) and 16 (0.17%) in the aspirin group. INTERPRETATION: Long-term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death. The overall safety profile of clopidogrel is at least as good as that of medium-dose aspirin

Multiplicity dependence of the average transverse momentum in pp, p-Pb, and Pb-Pb collisions at the LHC

The average transverse momentum (p(T)) versus the charged-particle multiplicity N-ch was measured in p-Pb collisions at a collision energy per nucleon-nucleon root S-NN = 5.02 TeV and in pp collisions at collision energies of root s = 0.9, 2.76, and 7 TeV in the kinematic range 0.15 < p(T) < 10.0 GeV/c and vertical bar eta vertical bar < 0.3 with the ALICE apparatus at the LHC. These data are compared to results in Pb-Pb collisions at root S-NN = 2.76 TeV at similar charged-particle multiplicities. In pp and p-Pb collisions, a strong increase of (p(T)) with N-ch is observed, which is much stronger than that measured in Pb-Pb collisions. For pp collisions, this could be attributed, within a model of hadronizing strings, to multiple-parton interactions and to a final-state color reconnection mechanism. The data in p-Pb and Pb-Pb collisions cannot be described by an incoherent superposition of nucleon-nucleon collisions and pose a challenge to most of the event generators. (C) 2013 CERN. Published by Elsevier B.V. All rights reserved

Corrigendum to "Measurement of the pp\u2192ZZ production cross section and constraints on anomalous triple gauge couplings in four-lepton final states at s=8TeV" [Phys. Lett. B 740 (2015) 250]

An error was found in the published version in the right plot in Fig. 4. The bin-by-bin normalization for data and MC prediction in this plot is incorrect. The corrected figure is shown in Fig. 1. The physics conclusion of the paper remains unchanged